Encompass Health (EHC)
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
$121.52+0.87%
Close 2026-09-09 · 1-day change
NYSEHealth CareMedical - Care FacilitiesSnapshot 2026-09-09
Intact: The reason to own it still holds.
Encompass Health grows revenue about 9% yearly by expanding hospitals. Profit rises with better cost control, shown by operating income up $50M year-over-year. Dividends keep growing steadily, reflecting strong cash flow. The company trades cheaper than peers with solid earnings growth.
Growth could slow if hospital expansions stall or costs rise. Profit margins might shrink if efficiency efforts fail. Debt from recent bond issuance could pressure capital allocation.
The stock trades about 14% above our fair value near $97. Analysts expect about 9.5% revenue growth, which aligns with company guidance. Our view is slightly more cautious on growth sustainability.
Breaks if: Dividend per share falls below $0.17 in FY26
Breaks if: Operating income falls below $238M in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
EHC represents a durable compounder with a focus on organic growth and profitability. The current thesis state is intact, supported by recent strong financial performance and management's commitment to key priorities.
The market appears to have a neutral valuation for EHC, with a slight expectation gap suggesting that some growth is already anticipated. Compared to peers, EHC is seen as relatively cheap, which may reflect a cautious outlook.
Fundamentals are likely to remain strong, given management's focus on increasing revenue and enhancing operating income. However, there is a moderate risk due to recent volatility in management and the potential for economic headwinds impacting performance.
The long-term thesis hinges on the ability of EHC to maintain its growth trajectory and manage risks associated with economic conditions. Key factors include the performance of sector bellwethers and the overall health of the job market.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports expectations for continued revenue growth. The company raised its guidance, indicating strong organic growth potential.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Focus on improving operating income through disciplined operating strategy and cost management.
Stated as a priority in 3 of last 3 quarters. Operating income increased from $236.8M in 2025-Q2 to $261.6M in 2026-Q2, and Adjusted EBITDA grew from $318.6M to $348.0M. Management's focus on disciplined operating strategy aligns with these improving profitability metrics, indicating delivering progress.
“Revenue increased 9.6% and Adjusted EBITDA grew 9.2% in Q2 2026.”
“First quarter revenue increased 9.0% and Adjusted EBITDA grew 11.2%.”
“Q4 revenue increased 9.9% and Adjusted EBITDA grew 15.9%.”
Breaks if: YoY revenue growth falls below 6% in FY26
Expand inpatient rehabilitation capacity by opening new hospitals and adding beds to existing facilities to drive revenue growth.
Stated as a priority in 3 of last 3 quarters. Revenue increased from $1.4577B in 2025-Q2 to $1.5974B in 2026-Q2 (+9.6%), with discharges growing 5.6%. Management consistently emphasized hospital openings and bed additions to drive organic growth, and the financials show delivering progress.
“Opened three hospitals totaling 139 beds and added 54 beds; expect five more hospitals and 100+ beds before year end.”
“Opened a new 49-bed hospital and added 44 beds across existing facilities; expect eight hospitals and 175 beds added in 2026.”
“Added 517 inpatient rehabilitation beds via eight new hospitals and 127 beds to existing hospitals in 2025.”
In the next 1 to 3 years, EHC's performance will depend on its execution of growth strategies and external economic factors. Not investment advice.